Gene transfer for the treatment of neovascular ocular disease (An American Ophthalmological Society Thesis)

Transactions of the American Ophthalmological Society

Volumn 104, Issue , 2006, Pages 530-560

  Stout, John Timothy ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEPROMAZINE; ANGIOSTATIC PROTEIN; COMPLEMENTARY DNA; ENDOSTATIN; ERYTHROMYCIN; KETAMINE; NEUROPILIN; OFLOXACIN; PLASMINOGEN; PREDNISOLONE; RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN RECEPTOR; VIRUS VECTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLINDNESS; CELL ISOLATION; CELL PROLIFERATION; CELL TRANSFORMATION; CORNEA NEOVASCULARIZATION; DISEASE COURSE; ELECTRORETINOGRAM; EYE DISEASE; EYE EXAMINATION; FUSION GENE; GENE SEQUENCE; GENE TRANSFER; GENETIC TRANSDUCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LENTIVIRINAE; MALE; MOLECULAR CLONING; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RETINA EDEMA; RNA ISOLATION; VIRAL GENE THERAPY;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROID; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; FLUORESCEIN ANGIOGRAPHY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HIV-1; HUMANS; IRIS; MACACA FASCICULARIS; MALE; PIGMENT EPITHELIUM OF EYE; RABBITS; RATS; RATS, INBRED BN; RATS, SPRAGUE-DAWLEY; RETINAL NEOVASCULARIZATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33947697178     PISSN: None     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Council on Scientific Affairs. Report of the organ transplant panel: corneal transplantation. JAMA 1988;259:719-722.
2. Gomez DE, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-122.
3. Bramhall SR, Stamp GW, Dunn J, et al. Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer 1996;73:972-978.
4. Docherty AJ, Lyons A, Smith BJ, et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985;318:666-669.
5. Martin DC, Ruther U, Sanchez-Sweatman OH, et al. Inhibition of SV40 T antigen-induced hepatocellular in TIMP-1 transgenic mice. Oncogene 1996;13:569-576.
6. 165-receptor binding. J Cell Biochem 2002;85:357-368.
7. Chibber R, Molinatti PA, Rosatto N, et al. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia 1997;40:156-164.
8. Stitt AW. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol 2003;75:95-108.
9. Yoon SS, Eto H, Lin CM, et al. Mouse Endostatin inhibits the formation of lung and liver metastases. Cancer Res 1999;59:6251-6256.
10. Shichiri M, Hirata Y. Anti-angiogenesis signals by Endostatin. FASEB J 2001;15:1044-1053
11. Lucas R, Holmgren L, Garcia I, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998;92:4730-4741.
12. O'Reilly MS. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS 1997;79:273-294.
13. Yamaguchi N, Anand-Apte B, Lee M. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding EMBO J 1999;18:4414-4423.
14. Hanai J, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 2002;277:16464-16469.
15. Troyanovsky B, Levchenko T, Mansson G, et al. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 2001;152:1247-1254.
16. Ji W-R, Barrientos LG, Llinas M, et al. Selective inhibition by Kringle-5 of human plasminogen on endothelial cell migration: an important process in angiogenesis. Biochem Biophys Res Commun 1998;247:414-419.
17. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997;61:246-257.
18. Sgadari C, Farber JM, Angiolillo AL, et al. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997;89:2635-2643.
19. Sgadari C, Angiolillo AL, Cherney BW, et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 1996;93:13791-13796.
20. Levy I, Paldi T, Shoseyov O. Engineering a bifunctional starch-cellulose cross bridge protein. Biomaterials 2004;25:1841-1849.
21. Schmidt-Wolf GD, Schmidt-Wolf IG. Non-viral and hybrid vectors in human gene therapy: an update. Trends Mol Med 2003;9:67-72.
22. Wells DJ. Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther 2004;11:1363-1369.
23. McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004;15:1022-1033.
24. Klonjkowski B, Denesvre C, Eloit M. Adenoviral vectors for vaccines. In: Seth P, ed. Adenoviruses: Basic Biology to Gene Therapy. Austin, Texas: RG Landes; 1999:163-173.
25. Romano G, Pacilio C, Giordano A. Gene transfer technology in therapy: current applications and future goals. Oncologist 1998;3:225-236.
26. Merten OW, Geny-Fiamma C, Douar AM. Current issues in adeno-associated viral vector production. Gene Ther 2005;12:51-61.
27. Buning H, Braun-Falco M, Hallek M. Progress in the use of adeno-associated viral vectors for gene therapy. Cells Tissues Organs 2004;177:139-150.
28. Lewis PF, Emerman M. Passage through mitosis is required for onco-retroviruses but not for the human immunodeficiency virus. J Virol 1994;68:510-516.
29. Levy JA, Conrat HF, Owens RA. Viruses using reverse transcription during replication. In: Virology. Upper Saddle River, New Jersey: Prentice Hall;1994:125-141.
30. Theoretical Biology and Biophysics Group. Landmarks of the genome. In: Kuiken C, Foley B, Hahn B, et al, eds. HIV Sequence Compendium. Los Alamos National Laboratory; 2000:v-viii.
31. + cells with a human immunodeficiency virus type 1-based retroviral Vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol 1996;70:2581-2585.
32. Simpson E. Immunotherapy and gene therapy. Drugs 2004;7:105-108.
33. Chinen J, Puck JM. Successes and risks of gene therapy in primary immunodeficiencies. J Allergy Clin Immunol 2004;113:595-603.
34. Flannery JG, Zolotukhin S, Vaquero MI, et al. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci USA. 1997;94:6916-6921.
35. Hematti P, Hong BK, Ferguson C, et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2004;2:e423.
36. Kuger EA, Durat PH, Tsokos MG, et al. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun 2000;268:183-191.
37. Boesiger J, Tsai M, Maurer M, et al. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent up regulation of Fc epsilon receptor I expression. J Exp Med 1998;188:1135-1145.
38. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
39. Yokoyama Y, Dhanabal M, Griffioen AW, et al. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 2000;60:2190-2196.
40. Scappaticci FA, Smith R, Pathak A, et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and anti-tumor efficacy in leukemia and solid tumors in mice. Mol Ther 2000;3:186-196.
41. Bergers G, Javaherian K, Lo KM, et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-812.
42. Cheng L. Human immunodeficiency virus type 2 (HIV-2) vector-mediated in vivo gene transfer into adult rabbit retina. Curr Eye Res 2002 24:196-201.
43. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998;43:245-269.
44. Varmus H. Age-related macular degeneration: status of research. Bethesda, Maryland: Department of Health and Human Service, National Institutes of Health, March 1997. Available at : http://www.nei.nih.gov/news/statements/ varmus.htm. Accessed Dec 20, 2005.
45. Bressler SB, Maguire MG, Bressler NM, et al. Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. Arch Ophthalmol. 1990;108:1442-1447.
46. Cao Y, Ji RW, Davidson D, et al. Kringle domains of human angiostatin, characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996;271:29461-29467.
47. Cao Y, Chen A, An SS, et al. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 1997;272:22924-22928.
48. Gao G, Li Y, Gee, S, et al. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 2002;277:9492-9497.
49. Coa R, Wu HL, Veitonmaki N, et al. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA. 1999;96:5728-5733.
50. Sumariwalla PF, Cao Y, Wu HL, et al. The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther. 2003;5:R32-39.
51. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Arch Ophthalmol 1994;112:489-499